Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act

Robin Feldman

PLOS Medicine, 2024, vol. 21, issue 4, 1-7

Abstract: In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004381 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 04381&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:1004381

DOI: 10.1371/journal.pmed.1004381

Access Statistics for this article

More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().